<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231126060186N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-20</date_registration>
      <primary_sponsor>Razi University</primary_sponsor>
      <public_title>Comparisons of transcranial direct current and transcranial pulsed current motion on anaerobic performance and neurophysiological responses.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects of transcranial direct current and transcranial pulsatile current stimulation on anaerobic performance and neurophysiological responses in basketball girls</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>15</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74034</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Supportive, Randomization description: In this study, the order of subject exposure to 3 different conditions (3 different types of electrical brain movement) will be randomized by Latin methods. For this purpose, first, using the www.random.org website, a number between 1 and 15 will be randomly assigned to each of the subjects as an identification code. Then, the English letters B, A and C will be assigned to the three intervention conditions and a Latin square will be created. In this case, a Latin square with three rows and three columns is created. Finally, participants number 1 to 5 are placed in the sequence of the first row, participants number 6 to 10 are placed in the sequence of the second row, and participants number 11 to 15 are placed in the sequence of the third row, Blinding description: In this double-blind study, the researcher and participants will be blinded to the type of transcranial electrical stimulation used and the location of stimulation in each session. In the present study, the neurostimulator device was used to induce electrical stimulation of the brain in three separate sessions and three different modes including: 1) direct anodal current stimulation of the left posterior-lateral prefrontal cortex (DLPFC), 2) anodal pulse current stimulation of the posterior cortex - Left lateral prefrontal (DLPFC), 3) sham stimulation (placebo effect) will be used. For this purpose, a person outside the research team will be responsible for applying electrical stimulation during the experimental session. In order to blind the participants, after they sit on a special chair, the electrical stimulation device of the brain is hidden from their sight and covered by a cover completely, and the electrodes will be placed on the desired areas by the examiner. In order to blind the researcher, before the intervention, the researcher leaves the laboratory and returns to the test site after the stimulation period has passed and the electrodes are removed and the stimulation device is turned off. Also, in the sham stimulation mode, according to standard protocols, the active current is induced on the head for 30 seconds to induce the same sensation as the active stimulation mode, and then the current is cut off and the stimulation is deactivated.</study_design>
      <phase>3</phase>
      <hc_freetext>Participants are healthy and trained basketball players..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: In this study, all the subjects were exposed to two intervention conditions with an interval of one week, including 1) direct electrical stimulation of the left posterior-lateral prefrontal anodal cortex (DLPFC), 2) electrical pulse electrical stimulation of the posterior-lateral prefrontal anodal cortex. The left frontal (DLPFC) will be located. In both conditions, the duration of stimulation is 20 minutes and the intensity of direct electrical stimulation is 2 milliamperes, and the intensity of pulsed stimulation is 1.5 milliamperes. In order to stimulate, the Neurostim stimulation device manufactured by Medina Teb Company will be used. The target areas in the brain are identified using the international brain mapping system 10-20, and the target areas are stimulated using two special stimulation electrodes and a special electroencephalogram cap. Intervention 2: Control group: In this research, in addition to two intervention sessions, all subjects are exposed to a control session including electrical brain movement in sham mode (placebo effect). All the details of the implementation of the protocol will be similar to the intervention mode, with the difference that in the control mode, electromagnetic is not performed and the electric current of the drive motor is deactivated after 30 seconds. The duration of the control condition will be 20 minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be shared after de-identifying the subjects.

When:
6 months after the results are published

To whom:
researchers

Conditions:
For meta-analysis research

Where to obtain:
If you need to receive documents, send an email to Mastoure Salimi, research researcher, at the email address: mastoure77.salimi@gmail.com.

How to obtain:
In case of official request, announcement of the relevant reasons and full details, the data will be sent via email after 72 hours.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Vahid Tadibi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taq Bostan, University Blvd., Razi University, Faculty of Sports Sciences</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714414971</zip>
        <telephone>+98 83 3427 9265</telephone>
        <email>vtadibi@yahoo.com</email>
        <affiliation>Razi University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Vahid Tadibi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taq Bostan, University Blvd., Razi University, Faculty of Sports Sciences</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714414971</zip>
        <telephone>+98 83 3427 9265</telephone>
        <email>vtadibi@yahoo.com</email>
        <affiliation>Razi University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Basketball girls with at least two years of experience in club sports in the field of basketball
age range 18 to 30 years
resident of Kermanshah city
body mass index 18.5 to 24.9 weight per square meter
certificate of non-prohibition of participation in sports training program from a doctor.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Suffering from various chronic cardiovascular, pulmonary and metabolic diseases
History of seizures, epilepsy or other types of neurological diseases
Abnormalities or musculoskeletal disorders
Smoking and alcohol consumption</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: In this study, all the subjects were exposed to two intervention conditions with an interval of one week, including 1) direct electrical stimulation of the left posterior-lateral prefrontal anodal cortex (DLPFC), 2) electrical pulse electrical stimulation of the posterior-lateral prefrontal anodal cortex. The left frontal (DLPFC) will be located. In both conditions, the duration of stimulation is 20 minutes and the intensity of direct electrical stimulation is 2 milliamperes, and the intensity of pulsed stimulation is 1.5 milliamperes. In order to stimulate, the Neurostim stimulation device manufactured by Medina Teb Company will be used. The target areas in the brain are identified using the international brain mapping system 10-20, and the target areas are stimulated using two special stimulation electrodes and a special electroencephalogram cap.</i_keyword>
      <i_keyword>Control group: In this research, in addition to two intervention sessions, all subjects are exposed to a control session including electrical brain movement in sham mode (placebo effect). All the details of the implementation of the protocol will be similar to the intervention mode, with the difference that in the control mode, electromagnetic is not performed and the electric current of the drive motor is deactivated after 30 seconds. The duration of the control condition will be 20 minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Peak anaerobic power. Timepoint: During the anaerobic test. Method of measurement: Monarch wheel (Monark ergomedic 894E).</prim_outcome>
      <prim_outcome>Average anaerobic power. Timepoint: During the anaerobic test. Method of measurement: Monarch wheel (Monark ergomedic 894E).</prim_outcome>
      <prim_outcome>Fatigue index. Timepoint: During the anaerobic test. Method of measurement: Monarch wheel (Monark ergomedic 894E).</prim_outcome>
      <prim_outcome>Rating of perceived exertion. Timepoint: During the performance of the anaerobic test, during the active recovery period after the performance of the anaerobic test. Method of measurement: Using a pressure perception scale of 6 to 20 borg.</prim_outcome>
      <prim_outcome>Amplitude of muscle electromyography. Timepoint: During the performance of the anaerobic test. Method of measurement: 16-channel wireless electromyography device (Noraxon model, Scottsdale, AZ85260).</prim_outcome>
      <prim_outcome>Feeling pain. Timepoint: During the performance of the anaerobic test, during the active recovery period after the performance of the anaerobic test. Method of measurement: Using a scale of 0 to 10.</prim_outcome>
      <prim_outcome>Heart beat. Timepoint: During the performance of the anaerobic test, during the active recovery period after the performance of the anaerobic test. Method of measurement: Monarch wheel (Monark ergomedic 894E).</prim_outcome>
      <prim_outcome>Sense of pleasure. Timepoint: During the performance of the anaerobic test, during the active recovery period after the performance of the anaerobic test. Method of measurement: Using an 11-item emotion scale.</prim_outcome>
      <prim_outcome>Arousal level. Timepoint: During the performance of the anaerobic test, during the active recovery period after the performance of the anaerobic test. Method of measurement: Using a 6-item scale of perceived arousal.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Razi University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-18</approval_date>
        <contact_name>Razi University Research Ethics Committee</contact_name>
        <contact_address>Taghbostan Blvd., Koi 110, in front of No. 54 Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
